Viewing nowPregabalin Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Dongkuk Pharmaceutical Co., Ltd.

MFDS item code 201109224 · Approved 2011.10.27 · Insurance code 653402530
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
This drug is used to treat peripheral and central neuropathic pain in adults and is used as an adjunctive treatment for partial seizures in epilepsy patients. It is also effective in alleviating muscle pain due to fibromyalgia. It improves various neurological pain and seizure symptoms.
Administer this medicine orally as pregabalin in 2 divided doses per day, with or without food. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function (see section 5, “Patients with renal impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, “Discontinuation”). 2. Epilepsy Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted by the kidneys in unchanged form after entering the systemic circulation. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be given after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosing regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: Supplemental dose refers to an additional dose given once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescent patients aged 12-17 years because there are insufficient safety and efficacy data.
This drug may increase the risk of suicidal thoughts or behaviors, so patients should immediately inform healthcare providers if they experience mood changes or depression symptoms during treatment. It should not be administered to patients with hypersensitivity to this drug or specific genetic metabolic disorders. Diabetic patients may experience weight gain while taking this drug, which may require adjustments in their blood sugar control medications. If symptoms of angioedema occur, use should be discontinued immediately, and elderly patients should be cautious of the risk of falls due to dizziness or drowsiness. This drug may cause blurred vision or changes in eyesight, so any abnormal symptoms should be discussed with healthcare providers. Abrupt discontinuation of this drug can result in withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so it should be gradually tapered under medical supervision. Patients with a history of drug abuse should use this drug cautiously due to the potential for misuse or dependence and should report any unusual behavior to healthcare providers. Patients with reduced renal function may require dose adjustments, and those with cardiovascular diseases should take caution. There is an increased risk of respiratory depression when taken in combination with other medications that have central nervous system depressant effects, so caution is needed during concurrent use. This drug should not be administered to pregnant women during early pregnancy due to the risk of fetal malformations unless in special cases, and women of childbearing age should use effective contraception. Breastfeeding women should consider discontinuing either breastfeeding or medication as this drug may pass into breast milk and affect infants. Dizziness and drowsiness are common side effects; thus, it is advisable to avoid driving or operating hazardous machinery after taking this drug. In case of overdose, confusion, drowsiness, depression, seizures, etc., may occur, requiring immediate medical attention.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, periorbital swelling, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, suicidal ideation, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, hypersensitivity, feelings of euphoria, decreased libido, depersonalization, paraphilia, agitation, mood instability, emotional decline, emotional elevation, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, motor coordination disorders, balance disorders, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory abnormalities, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, aphasia, myoclonus, decreased reflexes, movement abnormalities, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, activity tremors, syncope, delirium, hypokinesia, olfactory abnormalities, ageusia, writing difficulties, blurred vision, diplopia, peripheral vision loss, visual disturbances, visual field deficits, photophobia, dry eyes, conjunctival swelling, reduced vision, ocular pain, eye fatigue, increased tear secretion, ocular irritation, mydriasis, perceptual changes in depth of vision during shaking, strabismus, brightness of the visual field, vertigo, auditory hyperesthesia, first-degree heart block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, flatulence, hypersalivation, gastroesophageal reflux disease, oral sensory impairment, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, diaphoresis, muscle cramps, joint pain, back pain, limb pain, cervical cramps, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling intoxicated, altered sensations, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, elevated creatine phosphokinase levels, increased aspartate aminotransferase, elevated blood glucose, decreased platelet count, reduced potassium levels, weight loss, increased blood creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorders, drowsiness, confusional state, depression, agitation, restlessness, seizures, shock, symptoms similar to anaphylaxis, mucous membrane syndrome, erythema multiforme
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to prevent exposure to air or moisture. The storage temperature should be maintained between 15 to 30 degrees Celsius.
A hard capsule with an upper reddish-brown part and a lower white part containing white powder that is white or light yellow.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Dongkuk Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.